2. Academic Validation
  3. TAOK3 Facilitates Esophageal Squamous Cell Carcinoma Progression and Cisplatin Resistance Through Augmenting Autophagy Mediated by IRGM

TAOK3 Facilitates Esophageal Squamous Cell Carcinoma Progression and Cisplatin Resistance Through Augmenting Autophagy Mediated by IRGM

  • Adv Sci (Weinh). 2023 Sep 13;e2300864. doi: 10.1002/advs.202300864.
Mingchuang Sun 1,  Zhaoxing Li 1,  Xiaoyuan Wang 1,  Meirong Zhao 2,  Yuan Chu 1,  Zehua Zhang 1,  Kang Fang 1,  Ziying Zhao 1,  Anqi Feng 1,  Zhuyun Leng 1,  Jianing Shi 1,  Li Zhang 3,  Tao Chen 1,  Meidong Xu 1
Affiliations

Affiliations

  • 1 Endoscopy Center, Department of Gastroenterology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
  • 2 Shanghai East Hospital, Jinzhou Medical University, Liaoning, 121001, China.
  • 3 Department of Pathology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
PMID: 37705061 DOI: 10.1002/advs.202300864
Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the deadliest cancers because of its robust aggressive phenotype and chemoresistance. TAO kinase belongs to mitogen-activated protein kinases, which mediate drug resistance in multiple cancers. However, the role of TAO kinase in ESCC progression and chemoresistance has never been explored. Here, it is reported that TAOK3 augments cell Autophagy and further promotes ESCC progression and chemoresistance. Mechanistically, TAOK3 phosphorylates KMT2C at S4588 and strengthens the interaction between KMT2C and ETV5. Consequently, the nuclear translocation of KMT2C is increased, and the transcription of autophagy-relevant gene IRGM is further upregulated. Additionally, the inhibitor SBI-581 can significantly suppress cell Autophagy mediated by TAOK3 and synergizes with cisplatin to treat ESCC in vitro and in vivo.

Keywords

Autophagy; Chemoresistance; Esophageal squamous cell carcinoma; IRGM; KMT2C; TAOK3.

Figures
Products